AI assistant
DEXCOM INC — Director's Dealing 2020
Mar 11, 2020
30198_dirs_2020-03-10_76cdc460-882e-4839-8623-be137cc24b43.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2020-03-08
Reporting Person: DOUBLEDAY RICHARD (EVP Chief Commercial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-03-08 | Common Stock | A | 11748 | $0.001 | Acquired | 60308 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 10714 | Indirect |
Footnotes
F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2: Included in this number are 35,492 unvested restricted stock units, 11,748 of which were granted on March 8, 2020 and shall vest through March 8, 2023, 10,910 of which were granted on March 8, 2019 and shall vest through March 8, 2022 and 12,834 of which were granted on March 8, 2018 and shall vest through March 8, 2021.
F3: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.